Oncology and Hematology - Global Oncology Academy

449-464 of 743

Prostate Cancer: Lifestyle Recommendations During Androgen Deprivation Therapy
Prostate Cancer: Lifestyle Recommendations During Androgen Deprivation Therapy
On the Frontlines of Prostate Cancer
Prostate Cancer: Lifestyle Recommendations During Androgen Deprivation Therapy
Tanya Dorff, MD
- Tanya Dorff, MD
Patient-Centered Insights for Advanced Prostate Cancer Treatment
Patient-Centered Insights for Advanced Prostate Cancer Treatment
On the Frontlines of Prostate Cancer
Patient-Centered Insights for Advanced Prostate Cancer Treatment
Tanya Dorff, MD
- Tanya Dorff, MD
Maximizing Myeloma Outcomes With GPRC5D-Directed Therapy: Practical Expert Case Studies and Best Practices
Maximizing Myeloma Outcomes With GPRC5D-Directed Therapy: Practical Expert Case Studies and Best Practices
CME/CE
Maximizing Myeloma Outcomes With GPRC5D-Directed Therapy: Practical Expert Case Studies and Best Practices
0.25 credits
0.25 credits
Exercise in Multiple Myeloma: Balancing Benefits and Safety
Exercise in Multiple Myeloma: Balancing Benefits and Safety
Project Oncology®
Exercise in Multiple Myeloma: Balancing Benefits and Safety
Jens Hillengass, MD, PhD
- Jens Hillengass, MD, PhD
Advances in Prostate Cancer Care: Genetic Testing, Teamwork, and ARPIs
Advances in Prostate Cancer Care: Genetic Testing, Teamwork, and ARPIs
On the Frontlines of Prostate Cancer
Advances in Prostate Cancer Care: Genetic Testing, Teamwork, and ARPIs
Neal Shore, MD, FACS
- Neal Shore, MD, FACS
mCRPC Care: Predicting Outcomes with a Novel Cell-Free DNA Sequencing Assay
mCRPC Care: Predicting Outcomes with a Novel Cell-Free DNA Sequencing Assay
Global Oncology Academy
mCRPC Care: Predicting Outcomes with a Novel Cell-Free DNA Sequencing Assay
Scott Dehm, PhD
- Scott Dehm, PhD
Newly Diagnosed Multiple Myeloma: The Prognostic Significance of Lymphopenia
Newly Diagnosed Multiple Myeloma: The Prognostic Significance of Lymphopenia
Project Oncology®
Newly Diagnosed Multiple Myeloma: The Prognostic Significance of Lymphopenia
Preventing MGUS/SMM Progression to Multiple Myeloma with Dietary Interventions
Preventing MGUS/SMM Progression to Multiple Myeloma with Dietary Interventions
Global Oncology Academy
Preventing MGUS/SMM Progression to Multiple Myeloma with Dietary Interventions
Early-Stage Breast Cancer Care: Treatment Selection Strategies and Challenges
Early-Stage Breast Cancer Care: Treatment Selection Strategies and Challenges
Project Oncology®
Early-Stage Breast Cancer Care: Treatment Selection Strategies and Challenges
Adrienne Waks, MD
- Adrienne Waks, MD
Adjuvant Treatments for HR+/HER2- EBC: The Role of CDK4/6 and PARP Inhibitors
Adjuvant Treatments for HR+/HER2- EBC: The Role of CDK4/6 and PARP Inhibitors
MinuteCE®
Adjuvant Treatments for HR+/HER2- EBC: The Role of CDK4/6 and PARP Inhibitors
Erica L. Mayer, MD, MPH
1.50 program credits
- Erica L. Mayer, MD, MPH
1.50 program credits
Management of HER2-Low MBC Following First-Line Disease Progression
Management of HER2-Low MBC Following First-Line Disease Progression
MinuteCE®
Management of HER2-Low MBC Following First-Line Disease Progression
Peter Schmid, FRCP, MD, PhD
1.50 program credits
- Peter Schmid, FRCP, MD, PhD
1.50 program credits
Novel Neoadjuvant and Adjuvant Immunotherapy Strategies for GI Malignancies: The Evidence
Novel Neoadjuvant and Adjuvant Immunotherapy Strategies for GI Malignancies: The Evidence
MinuteCE®
Novel Neoadjuvant and Adjuvant Immunotherapy Strategies for GI Malignancies: The Evidence
Alan Venook, MD
1.25 program credits
- Alan Venook, MD
1.25 program credits
The Role of Biomarker-Driven Therapies in the Second-Line Treatment of Advanced Gastric/GEJ Cancers: What Do the Data Say?
The Role of Biomarker-Driven Therapies in the Second-Line Treatment of Advanced Gastric/GEJ Cancers: What Do the Data Say?
MinuteCE®
The Role of Biomarker-Driven Therapies in the Second-Line Treatment of Advanced Gastric/GEJ Cancers: What Do the Data Say?
Sara Lonardi, MD
1.25 program credits
- Sara Lonardi, MD
1.25 program credits
First-line Treatment of MSI-H/dMMR mCRC: The Role of Immunotherapy
First-line Treatment of MSI-H/dMMR mCRC: The Role of Immunotherapy
MinuteCE®
First-line Treatment of MSI-H/dMMR mCRC: The Role of Immunotherapy
Aparna R. Parikh, MD
1.25 program credits
- Aparna R. Parikh, MD
1.25 program credits
Immunotherapy-Based Approaches for First-Line Treatment of Advanced HCC: The Evidence
Immunotherapy-Based Approaches for First-Line Treatment of Advanced HCC: The Evidence
MinuteCE®
Immunotherapy-Based Approaches for First-Line Treatment of Advanced HCC: The Evidence
Alan Venook, MD
1.25 program credits
- Alan Venook, MD
1.25 program credits
Current Guideline Recommendations for Biomarker-Based Second-Line Treatment of mCRC
Current Guideline Recommendations for Biomarker-Based Second-Line Treatment of mCRC
MinuteCE®
Current Guideline Recommendations for Biomarker-Based Second-Line Treatment of mCRC
Aparna R. Parikh, MD
1.25 program credits
- Aparna R. Parikh, MD
1.25 program credits

29/11